Ospedale S. Bortolo Report issue

Academic/Hospital Phase 4

Organization Overview

First Clinical Trial
2011
NCT01578213
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2011

Timeline

NOW
  • Now

Alternative names

Ospedale S. Bortolo (USSL 6)

Active Ingredients

Drugs in Phase 4 Trials (1)

imatinib (gleevec) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 1
  • # of Trial APIs: 1